{"paper_id":"ddfdbebd-a215-4eac-ae5d-ec9756da8b0d","body_text":"Endometriosis is a chronic, benign, gynecological, heritable, condition that is considered by extrauterine growth of endometrial tissue, and it has been shown by mysterious etiology (1). The disease influences 6–10% of women of reproductive age (2) and results in severe and chronic pelvic pain, dyspareunia, dysmenorrhea infertility, and dyspareunia (3). The occurrence of endometriosis is 20–40% in infertile women, showing a harmful impact on the pregnancy rate of in vitro fertilization. Twin and family studies have revealed that genetic factors are related to endometriosis pathogenesis (4). Our knowledge about the etiology and pathophysiology of endometriosis is unclear yet. Nevertheless, the genetic aspects of endometriosis might assist in around half the variation in the susceptibility to the disease.\nGenes related to apoptosis have been revealed to be deregulated in endometriosis. Electron microscopic analyses have determined the existence of apoptotic bodies in endometrial tissue through the late-secretory phase with a significant reduction of endometrial cell apoptosis in endometriosis.\nIt has been shown that spontaneous apoptosis had decreased in the ectopic endometrium in comparison to the eutopic endometrium of endometriosis individuals. Besides, the apoptosis level were reduced in the eutopic endometrium of endometriosis women compared with control group. Therefore, the decrease response of endometrial tissue to the apoptosis pathway might be related to the development of endometriosis (5).\nThe possible mechanism for the reduction of apoptosis is associated with the well-known regulators of apoptosis, anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, which is bound to pro-apoptotic Bcl-2 associated X protein (Bax). Bax is a death-promoting member of the Bcl-2 family and induces apoptosis via hetero-dimerization with Bcl-2 protein. The apoptosis rate is determined by the relative level of expression of these 2 proteins, which interact physically with each other (6). The  Bax  gene is located on chromosome 19q13.3 with a promoter with four p53 protein binding sites and 6 exons (7). The  Bcl-2  gene is another member of the Bcl-2 family, which unlike the Bax protein inhibits apoptosis. It is mapped on chromosome 18q21.3, with 2 promoters, 3 exons, and 2 introns. Bcl-2 protein is situated on the mitochondrial outer membrane and prevents Bax from changing the membrane permeability (8).\nPrevious studies have identified novel single-nucleotide polymorphisms (SNP) in  Bax  and  Bcl-2  genes which are crucial factors in cell-cycle control and cell survival. A promoter SNP in the  Bcl-2  gene, the -938C \n > \n A genotype ( rs2279115 ), is identified to be associated with high  Bcl-2  gene expression and is related to some cancer developments (9–12). Another SNP mapped on the 5 \n ' \n  untranslated region of the  Bax  promoter, -248G \n > \n A ( rs4645878 ), has been defined to be linked to both downregulation of Bax protein (12) and different susceptibility to numerous cancers (13–17). To our knowledge, there is no report examining the association of  Bax  -248G \n > \n A and  Bcl-2  -938C \n > \n A SNPs with endometriosis. This work aimed to study the polymorphic variants of these proapoptotic and antiapoptotic genes,  Bax  -248G \n > \n A,  rs4645878  and  Bcl-2 - 938C \n > \n A,  rs2279115  SNPs, with endometriosis susceptibility in a sample of the Iranian population.\n\nIn this case-control association study, from May 2022 to February 2023, 252 women were enrolled (127 cases and 125 controls) from the Department of Obstetrics and Gynecology of Ali-ibn-Abi Taleb Educational hospital, Zahedan, Iran. The control group was age and sex-matched healthy women of the same ethnic background with regular menstrual cycles and had not received any hormone therapy in the past 6 months. The medical records, including laparoscopy, laparotomy for diagnosis, therapy of endometriosis, and other complementary diagnostic tests were collected by the clinicians and pathologists. The diagnosis of endometriosis was histologically inveterate via the presence of an endometrial gland and/or stroma in the lesions. The characteristics of the endometriosis group and controls are shown in table I. The mean ages of the endometriosis and control groups were 30.14  \n ± \n  7.22 and 31.28  \n ± \n  6.87 yr, respectively. The participant in the healthy group had no previous medical record of endometriosis. Individuals were excluded if they withdrew consent, non-Iranian citizenship, and/or previous medical history of chronic pelvic pain, dysmenorrhea, or dyspareunia.\nThe whole blood of the participants, case and controls, were collected in ethylenediaminetetraacetic acid-containing tubes. After DNA extraction using a commercial kit (DynaBio, Takapoozist, Iran) as followed by manufacturer's instructions, the all of extracted DNA was stored preoperatively in microtubes at -20 C until analyzed. The allelic discrimination of the  Bax  -248G \n > \n A and  Bcl -2 -938C \n > \n A gene SNPs,  rs4645878  and  rs2279115 , respectively, were analyzed by the polymerase chain reaction (PCR)-restriction fragment length polymorphism. The PCR primers of 2 SNPs were synthesized. The PCR program detail has been described in the previous study (18). The  MspI  and  BccI  restriction enzymes were utilized to digest the  Bax  and  Bcl -2 PCR products, as followed by separation via 3% agarose gel electrophoresis. Each assay was run with negative controls. A random 20% of the samples were genotyped again to obtain accurate and reproducible results. The PCR products are shown in figures 1 and 2.\nThe sample size was calculated by online version of sample size calculator server (https://clincalc.com/stats/SampleSize.aspx), where P1 was 3%, representing the frequency of the mutant allele in control, P2 was 14%, which signifies the frequency of the mutant allele in case, with study power set to 80% and 95% of confidence intervals with the obtained critical value of  \n < \n  2.0. P1 and P2 were determined based on the previously reported percentages (19). The minimum sample size was adjusted for a total of 200 subjects.\nThe characteristics of endometriosis cases and controls\nGenotyping of the  Bax  -248G \n > \n A rs4645878 polymorphism by PCR-RFLP. Lane M: 100 bp DNA ladder, Lane 1: Mutant homozygote AA (109 bp), Lane 2: Heterozygous AG (109 + 89 +20 bp), Lane 3: PCR wild homozygote GG (89 +20 bp).\nGenotyping of the  Bcl-2  -938C \n > \n Ars2279115 polymorphism by PCR-RFLP. Lane M: 50 bp DNA ladder, Lane 1: Mutant homozygote AA (149 + 103 bp), Lane 2: Heterozygous CA (252 + 149 + 103 bp), Lane 3: PCR wild homozygote CC (252 bp).\nThe study protocol was approved by the Ethics Committee of the Zahedan University of Medical Sciences, Zahedan, Iran (Code: IR.ZAUMS.REC.1401.073), and performed according to the guidelines of the Declaration of Helsinki. Informed consent was obtained from all participants.\nStatistical analyses were performed using the Statistical Package for the Social Sciences, version 21.0 (SPSS Inc, Chicago, IL). Student's  t  test was used to detect differences in baseline clinical characteristics between cases and healthy women. Hardy-Weinberg equilibrium in both groups was examined with the Chi-square test to ensure they were representative. Differences in genetic distribution between cases and healthy women were compared using Pearson's Chi-square test. We calculated OR and 95% CI to reveal the relative risk degree. The p-values  \n < \n  0.05 were regarded as significant.\n\nThis study enrolled 125 infertile endometriosis women and 127 healthy controls without any history of endometriosis. The average ages of the case and the control group were not significantly different. A study of endometriosis-associated symptoms and the number of deliveries among the case and the control group revealed significant differences between them. Symptoms such as chronic pelvic pain, dysmenorrhea, and dyspareunia, were more frequent among endometriosis women (p  \n < \n  0.001). No significant difference was found in body mass index, menstrual cycle length and period length, and spontaneous abortions among case and control groups. According to the data in the table, a significant difference was observed in the number of deliveries between the patients and the control group. Especially in the delivery of one child (p  \n < \n  0.001). Based on the clinical stages, 58.26% of cases had minimal/mild (I and II) endometriosis and 41.73% of them had moderate/severe (stage III and IV) endometriosis (Table I).\nThe genotypes and allele distributions of  Bcl-2  and  Bax  SNPs in endometriosis women and controls are listed in table II. The genotype frequencies of this SNP were in agreement with Hardy-Weinberg equilibrium in the case and healthy women (p = 0.03, and 0.38, respectively). No association in genotypes GG, GA, and AA was observed between case and control groups. Under the dominant model (GG vs. GA+AA), we observed a significant association between  Bax  -248G \n > \n A variant and about 2-fold higher risk of endometriosis in contrasted genetic models. Interestingly, investigation of allele frequencies at  Bax -248G \n > \n A,  rs4645878,  revealed significant increases of the mutant allele A, approximately 2-fold, in cases compared with the controls (p = 0.01) (Table II).\nOur data showed that the frequency of the  Bcl-2   -938C \n > \n A,  rs2279115 , homozygous mutant variant AA was significantly higher in cases compared to controls (OR: 3.859; p = 0.001). In addition, under the dominant CA and AA combined vs. CC model, a significantly higher risk of endometriosis was observed. Furthermore, under the recessive model (AA vs. CC+CA), a significant difference of  Bcl- 2 -938C \n > \n A gene polymorphism with approximately 3-fold increase of endometriosis risk was observed. Interestingly, investigation of allele frequencies revealed significant increases, approximately 2-fold, of the mutant allele A in endometriosis women compared with the controls (Table II).\nAfter that we combined these 2 SNPs for association with endometriosis. Our data showed that the  Bax  -248G \n > \n A  rs4645878  GG and ,  the  Bcl -2 -938C \n > \n A  rs2279115  AA were classified as adverse genotype combinations based on association with about 5 times higher risk of endometriosis. In addition, we found that the combination of the  rs4645878  GG with, the  rs2279115  CC or  rs2279115  CA, significantly increased the risk of endometriosis. No statistically significant association was observed between other genotypic combinations of 2 SNPs (Table III).\nWhile women with minimal/mild endometriosis and moderate/severe endometriosis were considered distinctly, there were some differences for  Bax  -248G>A rs4645878 and,  Bcl -2 -938C>A rs2279115 SNPs. Considering the  Bax  -248G \n > \n A SNP, there was a significant difference in A allele distribution between minimal/mild (stage I and II) and moderate/severe (stage III and IV) women which revealed that A allele was found about 2.5-fold frequent in moderate/severe endometriosis than minimal/mild one. On the other side, moderate/severe endometriosis risk was about 5 times greater in cases with  Bcl-2  -938 C \n > \n A CA+AA genotype, which proposed that A allele might be a high-risk allele and could have a special effect on the severity of endometriosis disease (Table IV).\nGenotype and allele frequencies of  Bax  -248 G \n > \n A and  Bcl-2  -938 C \n > \n A gene polymorphism in controls and endometriosis women\nThe combination effects of  Bax  -248 G \n > \n A and  Bcl-2  -938 C \n > \n A gene polymorphism on endometriosis risk\nAssociation between  Bax  -248G \n > \n A and  Bcl-2  -938C \n > \n A gene polymorphism with clinical stage frequency in endometriosis women\n\nIn the current study, we investigated the association of the SNPs in  Bax  and  Bcl-2  genes, involved in apoptosis, with the risk of endometriosis. The presented study is the first attempt to evaluate the role of  Bax  -248G/A and  Bcl-2  -938C/A SNPs on the susceptibility to the disease. A statistically significant increased endometriosis rate was observed in cases with the  Bax  -248G \n > \n A variant (A allele) and\nGA+AA dominant genotype. Furthermore, cases with the  Bcl-2  -938C \n > \n A mutant A allele or AA variant and CA+AA vs. CC model exhibited an elevated risk of endometriosis. We also reported about 3 times or greater risk of endometriosis when a combination of  Bcl-2  -938C \n > \n  A and  Bax  -248G \n > \n  A were studied. There was a statistical association between  Bcl-2  -938C/A and  Bax  -248G \n > \n  A polymorphism and moderate/severe (stage III and IV) disease in these cases. It is worth noting that the percentage of cases studied is limited to stage III/IV endometriosis instead of stage I/II, which indicates that moderate to severe stages of the disease have a higher genetic burden compared to minimal or mild endometriosis.\nThe relationship between SNPs and the development of diseases has long been accepted. Recent improvements in molecular biology techniques have resulted in attention to SNPs and their impact on the risk assessment and development of diseases (20). Female fertility is strongly affected by genetic causes, and several reports have intended to recognize important genes in diseases that influence female fertility such as recurrent pregnancy loss, pre-eclampsia, fibroids, polycystic ovary syndrome, endometriosis, option rates (21), with a strong genetic basis (22). Apoptosis as a form of programmed cell death is very important to women's reproduction according to its involvement in the turnover of endometrial cells, remodeling of the uterine spiral arteries, embryonic development, and immunologic tolerance of maternal placental (23). The rate of apoptosis is reduced in the endometrial cells of women with endometriosis (24). Apoptosis is triggered by 2 different sources, intrinsic and extrinsic pathways, which ultimately lead to irreversible cell death (25).\nBcl-2  has 2 promoters with different functions in the regulation of its expression, that is, the P2 promoter is mapped on the translation start site and performs as a negative regulator of the P1 promoter (26). The common SNP in the  Bcl-2  gene was -938C \n > \n A (rs2279115) in P2 and its mutant allele displayed a significant increase in  Bcl-2  promoter activity. High  Bcl-2  over-expression saves cells from programmed death via enhancement of the stability of the mitochondrial outer membrane; therefore, stopping the intrinsic apoptotic pathway (27). The different  Bcl-2  gene expression, in the eutopic endometrium of women with endometriosis, caused reduced apoptotic cells and subsequently resulted in abnormal endometrial cells survival in the ectopic site (28).\nThe expression of  Bax , as a pro-apoptotic gene in the  Bcl-2  family, with a pro-apoptotic role in the mitochondrial pathway ,  has a significant impact on the release of apoptosis-related proteins. Although some reports revealed that  Bax  -248G \n > \n A was associated with the  Bax  protein expression (7), the exact effect of the SNPon protein expression is controversial. Related to the A allele, higher  Bax  mRNA and protein expression were reported to be associated with G alleles (29). Besides, another study revealed it caused lower transcriptional activity for  Bax  (30). As well as another study proposed that there was no association between the SNP and  Bax  transcriptional activity (31). Recent meta-analyses proposed that the downregulation of Bax protein is not connected to the poor prognosis for some cancers. Therefore, its polymorphism might not enhance cancer susceptibility and affect the prognosis of the tumors. In addition,  Bax  -248G \n > \n A and  Bcl-2  -938C \n > \n A SNPs have no direct association with overall cancer susceptibility nevertheless the relationship might have established ethnic specificity, and might be associated with increasing adverse prognosis of some cancers (32). Another study reported an increased susceptibility to leukemia having  Bcl-2  -938C \n > \n A and  Bax  -248G \n > \n A SNPs that influenced their response to treatment and overall survival. The data specified that there was an association between the mutant allele of  Bcl-2 -938C \n > \n A C \n > \n A and the  Bax  -248G \n > \n A gene and a significantly increased risk of developing leukemia, compared to the wild-type allele (17). There are few studies on the relation of these polymorphisms to fertility-associated diseases. There are only 2 reports that study the effect of  Bcl-2 -938C \n > \n A  C \n > \n A and  Bax  -248G \n > \n A on women's fertility-related disorders.\nIn the first report, it was assessed if these SNPs are related to unexplained recurrent pregnancy loss risk in a Brazilian population (33). They propose that the  Bax -248G \n > \n A  AG genotype is a protective genotype for primary recurrent pregnancy loss and that the  Bcl - 2  -938 CC and C are risk factors for secondary recurrent pregnancy loss. Another study investigated the probable impact of the placental  Bax  and  Bcl-2  polymorphisms on pre-eclampsia susceptibility and found that there was no relationship between pre-eclampsia and placental  Bax rs4645878  and  Bcl-2 rs2279115  SNPs (18).\nThe main limitation of our report is the relatively small sample size of the endometriosis group, which could lead to reduction in the statistical power for identification of relations between the studied SNPs and the disease. Nevertheless, the limitation was the consequence of selection criteria because all endometriosis women who participated in this analysis were confirmed via laparoscopy and were classified based on the endometriosis stage with histologic confirmation. However, another study with larger sample sizes is needed to validate our results.\n\nThe results suggest that the  Bax  -248G \n > \n A,  rs4645878  and  Bcl-2  -938C \n > \n A,  rs2279115  single nucleotide polymorphisms play a significant role in the pathogenesis of endometriosis in Iranian women. Our current study is just the first of this kind for proof-of-principle. Possibly, polymorphic variants of  Bax  -248G \n > \n A and  Bcl-2  -938C \n > \n A promoter regions might result in the altercations in transcription factor binding to the promoter, leading to the change of gene expressions, which might be associated with endometriosis.\n\nAll related data and materials are available from the corresponding authors upon request.\n\nDJ, FF, and MT conceived and designed the study. AEKh and MR did the data curation. SGhZ and DJ conducted the data analysis and drafted the initial manuscript. AEKh, FF, MR, and MT helped with the interpretation of the results and gave critical comments on the manuscript. All authors contributed to the final version of the manuscript.\n\nThe authors declare that there is no conflict of interest.","source_license":"CC0","license_restricted":false}